I’ah Donovan-Banfield

Sep 25, 2023 | nature.com | Theo Sanderson |I’ah Donovan-Banfield |Thomas Peacock

AbstractMolnupiravir, an antiviral medication widely used against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), acts by inducing mutations in the virus genome during replication. Most random mutations are likely to be deleterious to the virus and many will be lethal; thus, molnupiravir-induced elevated mutation rates reduce viral load1,2.